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2 courses of consolidation chemotherapy were 81.1/41.3 %, 41.4/29.7 
% and 59.7/50.0 %, respectively. Major toxicities were as follows; G4 
neutropenia in MVP, IC, PC were 76.9, 13.1, 4.2 % (p<.001), and G3-4 
non-hematological toxicities (decrease in PS, and febrile neutropenia) 
were 13.3, 6.2, 4.2 % (p=.01), and 29.4, 6.9, 4.9 % (p<.001), respec-
tively. The overall response rates were 65.7 % (95%CI 57.9-73.5), 58.6 
% (95%CI 50.5-66.1) and 62.9 % (95%CI 55.0-70.8), in MVP, IC and 
PC, respectively. Complete analysis will be ﬁxed in Oct 2008. 
Conclusions: Weekly PC with TRT appears good compliance with 
high achievement rate and MVP appears poor compliance with severe 
hematological and non-hematological toxicities.
C3-04 Combined Modality Therapy in NSCLC II, Wed, 10:30 - 12:15
Phase III study comparing a preoperative (PRE) and a 
perioperative (PERI) chemotherapy (CT) with two different 
CT regimens in resectable stage I-II non-small cell lung cancer 
(NSCLC): the IFCT 0002 protocol
Depierre, Alain .1 Milleron, Bernard2 Quoix, Elisabeth3 Puyraveau, 
Marc4 Braun, Denis5 Breton, Jean-Luc6 Bigay-Game, Laurence7 Pujol, 
Jean-Louis8 Morin, Franck9 Westeel, Virginie4 
1 Centre Hospitalier Universitaire de Besancon, Université de Franche-
Comté, Besancon, France 2 Centre Hospitalier Universitaire Tenon, AP-
HP, Paris, France 3 Hôpitaux Universitaires de Strasbourg, Strasbourg, 
France 4 Centre Hospitalier Universitaire de Besançon, Besançon, 
France 5 Centre Hospitalier de Briey, Briey, France 6 Centre hospitalier 
de Montbéliard-Belfort, Belfort, France 7 Centre Hospitalier Universi-
taire de Toulouse, Toulouse, France 8 Centre Hospitalier Universitaire 
de Montpellier, Montpellier, France 9 Intergroupe Francophone de 
Cancérologie Thoracique (IFCT), Paris, France 
Background: The association of surgery and chemotherapy is now 
a standard in stages IA-III. The primary objective of this trial was to 
deﬁne the best timing of CT (all before surgery versus perioperative). 
Another objective was to compare two regimens, gemcitabine-cisplatin 
(GP) and paclitaxel-carboplatin (TC) (GP: Gemcitabine 1250 mg/m2/
d1, 8 and cisplatin 75 mg/m2/d1 q3 wk; TC: Paclitaxel 200 mg/m2/d1 
and carboplatin AUC 6, q3 wk).
Methods: 528 stage I-II resectable NSCLC were randomized to 4 
parallel arms: A: 2 GP + in responders, 2 GP, then surgery, B: 2 GP + 
surgery + in responders, 2 GP, C: 2 TC cycles + in responders, 2 TC 
then surgery, D: 2 TC + surgery + in responders, 2 TC. Quality of life 
was evaluated with the EORTC QLQ C30 - LC13 questionnaire at days 
1, 42 and 147. Results were analyzed two by two: PRE (A+C) versus 
PERI (B+D) and GP (A+B) versus TC (C+D).
Results: 1) The addition of 2 additionnal preoperative CT cycles in 
responders did not inﬂuence tumor volume, intratumoral necrosis, 
pleural, venous or intrapulmonary lymphatic invasions. Pathological 
complete response rates were not statistically different (PRE: 6.3%, 
PERI: 7.6%, GP: 8.2%, TC: 5.6%). Objective responses were simi-
lar (PRE: 50.6%, PERI: 50.9%, GP: 52.2%, TC: 49.2%) 2) 30-day 
postoperative mortality were identical whether the patient received 2 
or 4 cycles before surgery. Similarly, iatrogenic mortality at 6 months 
did not differ with the number of preoperative CT cycles (PRE:3%, 
PERI:3.21%). The main toxicities differs betweeen GP and TC only for 
G ≥2 neuropathy at 6 months (GP: 6.5%, TC: 24.4%, p<10-3) and G ≥2 
nausea (GP: 22.17%, TC: 4.22%, p<10-3) .3) Proportions of pts receiv-
ing cycles 3 and 4 were higher when they were given before surgery 
than after surgery (PRE: 90.4%, PERI:75.2 %, p=.0011). Percentages 
of non operated pts after CT were identical in both groups (PRE: 4.5%, 
PERI: 4.3%). 4) There was no difference in Quality of Life between 
the 4 groups. At 6 months, decrease of health status, different function-
ning and symptoms did not differ between the 4 arms in responding pts 
(except for alopecia).
Conclusions: 1- GP and TC were both effective and safe, although 
with different toxicity proﬁles. 2- Results of pathological response 
suggested that 2 preoperative cycles might be as effective as 4 cycles. 
3- Dose intensity was higher when all chemotherapy was given before 
surgery compared to both before and after surgery. 4- Quality of life 
decrease in the same proportions in each group within the 6 months 
after randomization.
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Background: A previous IPD meta-analysis (BMJ 1995;311:899) 
that suggested cisplatin-based CT may have a role in the treatment of 
NSCLC has been updated. This includes RCTs, regimens and outcomes 
that were not available in 1995. The meta-analysis examines the role 
of CT in 7 treatment comparisons. Here we report on Comparison 1: 
surgery + CT versus surgery alone and Comparison 3: surgery + RT + 
CT versus surgery + RT.
Methods: RCTs were identiﬁed by comprehensive search strategies. 
Updated IPD were collected, checked and re-analysed. Results from 
RCTs were combined using the stratiﬁed (by trial) logrank test to calcu-
late individual and pooled hazard ratios (HRs).
Results: Comparison 1
IPD were obtained from 30 RCTs and 8147 patients, representing 
95% of all known randomised patients, adding 18 RCTs and 5835 
patients to the 1995 analyses. Median follow-up is 5.3 years. 15 RCTs 
used a cisplatin combination without Tegafur/Tegafur+Uracil (UFT), 
8 RCTs used Tegafur/UFT without cisplatin and 7 RCTs used Tega-
fur/UFT and cisplatin. There is a signiﬁcant beneﬁt of CT on survival 
(HR=0.86, 95% CI 0.81-0.93, p<0.0001), with an absolute beneﬁt of 
4% (from 60% to 64%) at 5 years. Results were similar for recurrence-
free survival (HR=0.83, 95%CI 0.77-0.91, p<0.0001, 14 RCTs) local 
(HR=0.76, 95% CI 0.66-0.87, p<0.0001, 12 RCTs) and distant recur-
rence-free interval (HR=0.83, 95% CI 0.74-0.93, p=0.001, 12 RCTs).
Comparison 3
IPD were obtained from 11 RCTs and 2,626 patients (12% with incom-
plete resection), representing 86% of all known randomised patients, 
adding 5 RCTs and 1956 patients to the 1995 analysis. Median follow-
up is 6.3 years. 10 RCTs used sequential radio-chemotherapy, 8 RCTs 
used cisplatin + vinca alkaloid/etoposide, 1 used cisplatin + Tegafur 
and 2 used other cisplatin regimens. There is a signiﬁcant beneﬁt of 
CT on overall survival (HR=0.88, 95% CI 0.80-0.96, p=0.0062), with 
an absolute beneﬁt of 5% (from 29% to 34%) at 5 years. Results were 
similar for recurrence-free survival (HR=0.84, 0.77-0.93, p=0.0006, 
